Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

OncoSec Medical Inc. Reports ImmunoPulse May Prolong Survival Based On Analysis Of Long-Term Survival Data From Phase I Study In Melanoma

December 4, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based cancer immunotherapies, released long-term survival results from its Phase I study in patients with metastatic melanoma, evaluating a single treatment cycle of intratumoral plasmid IL-12 (pIL-12) injection with electroporation (EP). Dr. Robert Pierce, Chief Scientific Officer at OncoSec, a co-author of the…

Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference

December 4, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 4, 2014 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York City.  

The live presentation takes place on Wednesday, December 10 at 10:55am ET (7:55am PT).  The presentation will be webcast and may be accessed on the Company’s website at http://www.neurocrine.com.   Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.  The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.  Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company’s website via the internet at http://www.neurocrine.com.

SOURCE Neurocrine Biosciences, Inc.

Zogenix, Inc. To Participate In Oppenheimer 25th Annual Healthcare Conference

December 4, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Stephen Farr, President, and Ann Rhoads, Chief Financial…

Arcturus Therapeutics To Present At The

December 4, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 3, 2014 /PRNewswire/ –Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing orphan diseases, today announced its participation on two panel discussions at the Genetic Rx Conference taking place at Harvard Medical School on December…

Neurocrine Biosciences, Inc. To Present At The 25th Annual Oppenheimer Healthcare Conference

December 4, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 4, 2014 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York City…

Neurocrine Biosciences, Inc. To Present At The 25th Annual Oppenheimer Healthcare Conference

December 4, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 4, 2014 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York City…

Arcturus Therapeutics To Present At The

December 4, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 3, 2014 /PRNewswire/ –Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing orphan diseases, today announced its participation on two panel discussions at the Genetic Rx Conference taking place at Harvard Medical School on December…

Evofem, Inc. Appoints <b>Chad Putnam</b> As Chief Financial Officer

December 4, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 2, 2014 (GLOBE NEWSWIRE) — Evofem, Inc. announced that it appointed Chad Putnam as Chief Financial Officer effective immediately. Mr. Putnam will report to Saundra Pelletier, Chief Executive Officer of Evofem, Inc.

Cytori Therapeutics, Inc.’ Investor Presentation Now Available For On-Demand Viewing

December 4, 2014 – 5:00 pm | Edit Post

NEW YORK and SAN DIEGO, Dec. 5, 2014 /CNW/ — Cytori Therapeutics (NASDAQ: CYTX), today announced that the presentation and corporate update given on December 4 by President and CEO Marc Hedrick, M.D. is now available for on-demand viewing at VirtualInvestorConferences.com.LINK: http://virtualinvestorconferences.com > red “watch company presentations now” buttonCytori’s presentation…

NEMUS To Move Forward With Cannabinoid-Based Therapy For Open-Angle Glaucoma

December 4, 2014 – 5:00 pm | Edit Post

COSTA MESA, Calif., Dec. 4, 2014 (GLOBE NEWSWIRE) — NEMUS Bioscience, Inc. (OTC:NMUS) reports that data recently presented at the American Association of Pharmaceutical Scientists (AAPS) meeting in San Diego by Dr. Soumyajit Majumdar, Associate Professor of Pharmaceutics, University of Mississippi…